Ulcerative Colitis Partnering 2009-2014

  • November 2014
  • -
  • Currentpartnering
  • -
  • 100 pages

The Ulcerative Colitis Partnering 2009-2014 report provides understanding and access to the ulcerative colitis partnering deals and agreements entered into by the worlds leading healthcare companies.

-Trends in ulcerative colitis partnering deals
-Top ulcerative colitis deals by value
-Deals listed by company A-Z, industry sector, stage of development, technology type

The Ulcerative Colitis Partnering 2009-2014 provides understanding and access to the ulcerative colitis partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of ulcerative colitis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors ulcerative colitis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 50 links to online copies of actual ulcerative colitis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of ulcerative colitis partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in ulcerative colitis partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading ulcerative colitis deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of ulcerative colitispartnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of ulcerative colitis technologies and products.

Report scope

Ulcerative Colitis Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to ulcerative colitis trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

-Trends in ulcerative colitis dealmaking in the biopharma industry since 2009
-Access to summary headline, upfront, milestone and royalty data
-Access to over 50 ulcerative colitis contract documents
-The leading ulcerative colitis deals by value since 2009

In Ulcerative Colitis Partnering 2009-2014, the available deals are listed by:

-Headline value
-Upfront payment value
-Royalty rate value
-Company A-Z
-Industry sector
-Stage of development at signing
-Deal component type
-Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Table Of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in ulcerative colitis partnering

2.1. Introduction
2.2. Ulcerative colitis partnering over the years
2.3. Big pharma ulcerative colitis dealmaking activity
2.4. Big biotech ulcerative colitis dealmaking activity
2.5. Most active ulcerative colitis dealmakers
2.6. Ulcerative colitis partnering by deal type
2.7. Ulcerative colitis partnering industry sector
2.8. Ulcerative colitis partnering by stage of development
2.9. Ulcerative colitis partnering by technology type
2.10. Disclosed financial deal terms for ulcerative colitis
2.10.1 Ulcerative colitis headline values
2.10.2 Ulcerative colitis upfront payments
2.10.3 Ulcerative colitis milestone payments
2.10.4 Ulcerative colitis royalty rates

Chapter 3 - Leading ulcerative colitis deals

3.1. Introduction
3.2. Top ulcerative colitis deals by value

Chapter 4 - Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type

Chapter 5 - Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Ulcerative colitis partnering since 2009
Figure 2: Big pharma - top 50 - ulcerative colitis deals 2009 to 2014
Figure 3: Big pharma ulcerative colitis deal frequency - 2009 to 2014
Figure 4: Big biotech - top 50 - ulcerative colitis deals 2009 to 2014
Figure 5: Big biotech ulcerative colitis deal frequency - 2009 to 2014
Figure 6: Ulcerative colitis dealmaking activity- 2009 to 2014
Figure 7: Ulcerative colitis partnering by deal type since 2009
Figure 8: Ulcerative colitis partnering by industry sector since 2009
Figure 9: Ulcerative colitis partnering by stage of development since 2009
Figure 10: Ulcerative colitis partnering by technology type since 2009
Figure 11: Ulcerative colitis deals with a headline value
Figure 12: Ulcerative colitis deals with upfront payment values
Figure 13: Ulcerative colitis deals with milestone payments
Figure 14: Ulcerative colitis deals with royalty rates, %
Figure 15: Top ulcerative colitis deals by value since 2009
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cance ...

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

Global Mobile Healthcare Market Devices, Applications, Services Industry Size, Analysis, Market Report, Share, Growth, Trends and Forecast 2014-20

Global Mobile Healthcare Market Devices, Applications, Services Industry Size, Analysis, Market Report, Share, Growth, Trends and Forecast 2014-20

  • $ 7 000
  • Industry report
  • November 2014
  • by Occams

According to WHO approximately 17.3 million people die annually due to CVD and the condition is responsible for 30 percent of the global deaths. Also, 80 percent of CVD deaths take place in low and middle ...


10 Companies

Company Profiles


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.